sacituzumab govitecan-hziy + cyclophosphamide + N-803 + PD-L1 t-haNK

This is a **combination cancer therapy** consisting of four distinct agents: - **Sacituzumab govitecan-hziy**: an antibody-drug conjugate targeting Trop-2 that delivers SN-38, a topoisomerase I inhibitor, directly to Trop-2–expressing tumor cells, causing DNA damage and cell death. - **Cyclophosphamide**: a classical alkylating agent (chemotherapy), interfering with DNA replication and leading to apoptosis in cancer cells. - **N-803**: an IL-15 superagonist cytokine, stimulating immune cell proliferation and activation, mainly of NK cells and CD8+ T cells to enhance antitumor immunity. - **PD-L1 t-haNK**: a genetically engineered high-affinity natural killer cell line expressing a PD-L1-targeting chimeric antigen receptor (CAR), high-affinity CD16, and retained IL-2, designed to specifically target and kill PD-L1-expressing tumor cells and myeloid-derived suppressor cells via cytotoxicity pathways (perforin/granzyme, caspase activation)[1][2][3][5]. The combination leverages **targeted cytotoxicity, classic chemotherapy, cytokine stimulation, and cellular immunotherapy** for synergistic antitumor activity, investigated primarily in difficult-to-treat solid tumors[2][4].

Brand names

Trodelvy

Other names

sacituzumab govitecan-hziycyclophosphamideN-803N803N 803PD-L1 t-haNKPD-L-1 t-haNKPD-L 1 t-haNK